

Curriculum Vitae

Thomas Muley Dr. sc. hum.
d.o.b. 27.11.1958, in Mannheim, Germany

University Education

1990 Dr. sc. hum, Dept. of Pharmacology, Ruprecht-Karls University Heidelberg
1992–1986 Studies of Biology, Ruprecht-Karls University Heidelberg

Scientific Career

2011- 2019 Co-coordinator, DZL platform biobank and data management
Since 2009 Head, clinical tumor registry, Thoraxklinik, University Heidelberg
Since 2005 Group leader and assistant manager of Sektion Translationale Forschung (STF),
Thoraxklinik, University Heidelberg
Since 2000 Head, Lungbiobank, Thoraxklinik, University Heidelberg
1995-2005 Senior Research Scientist, Dept. of Surgery, Thoraxklinik, University of Heidelberg
1990-1995 Postdoctoral Fellow, Department of Clinical Chemistry and Bacteriology,
Thoraxklinik, University of Heidelberg

Citation Record

*Total citations: 15.245; h-index:50; h-index since 2017: 23 (Web of Science Sept 29th, 2022)
16.185; h-index:55 (Researchgate Sept 29th, 2022).*

Top-10 selected Publications (10/253)

Yaung SJ, Woestmann C, Ju C, Ma XM, Gattam S, Zhou Y, Xi L, Pal S, Balasubramanyam A, Tikoo N, Heussel CP, Thomas M, Kriegsmann M, Meister M, Schneider MA, Herth FJ, Wehnl B, Diehn M, Alizadeh AA, Palma JF and **Muley T**. Early Assessment of Chemotherapy Response in Advanced Non-Small Cell Lung Cancer with Circulating Tumor DNA. **Cancers** 2022, 14: 2479 doi: 10.3390/cancers14102479

Kim-Wanner SZ, Assenov Y, Nair MB, Weichenhan D, Benner A, Becker N, Landwehr K, Kuner R, Sultmann H, Esteller M, Koch I, Lindner M, Meister M, Thomas M, Bieg M, Klingmueller U, Schlesner M, Warth A, Brors B, Seifried E, Bonig H, Plass C, Risch A, **Muley T**. Genome-wide DNA methylation profiling in early stage I lung adenocarcinoma reveals predictive aberrant methylation in the promoter region of the long non-coding RNA PLUT - an exploratory study. **J Thorac Oncol**. 2020 Apr 6. pii: S1556-0864(20)30287-2. doi: 10.1016/j.jtho.2020.03.023.

Ji X, Mukherjee S, (...), **Muley T**, Risch A, (...), , Amos CI. Protein-altering germline mutations implicate novel genes related to lung cancer development. **Nat Commun**. 2020, 11;11(1):2220. doi: 10.1038/s41467-020-15905-6.

Lukassen S, Chua RL, Trefzer T, Kahn NC, Schneider MA, **Muley T**, Winter H, Meister M, Veith C, Boots AW, Hennig BP, Kreuter M, Conrad C, Eils R. SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells. **EMBO J**. 2020, 14:e105114. doi: 10.15252/embj.2020105114.

Dabral S, Muecke C, Valasarajan C, Schmoranzler M, Wietelmann A, Semenza GL, Meister M, **Muley T**, Seeger-Nukpezah T, Samakovlis C, Weissmann N, Grimminger F, Seeger W, Savai R, Pullamsetti SS. A RASSF1A-HIF1 α loop drives Warburg effect in cancer and pulmonary hypertension. **Nat Commun**. 2019 May 13;10(1):2130.

George, J; Lim, JS; (...); **Muley T**, (...), Thomas, RK. Comprehensive genomic profiles of small cell lung cancer. **Nature** 2015, 524 (7563) , pp.47-53

Collisson, EA; (...); **Muley T**, (...); Tsao, MS Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma **Nature** 2014, 511 (7511) :543-550

Muley T, Dienemann H, Herth, FJF, Thomas M, Meister M; Schneider J: Combination of Mesothelin and CEA Significantly Improves the Differentiation between Malignant Pleural Mesothelioma, Benign Asbestos Disease, and Lung Cancer. **J Thorac Oncol**. 2013 Jul;8(7):947-51. doi: 10.1097/JTO.0b013e31828f696b

Muley T, Herth FJF, Schnabel P, Dienemann H, Meister M.
From tissue to molecular phenotyping: Pre-analytical requirements Heidelberg Experience.
Transl Lung Cancer Res 2012;1(2):111-121

Muley T, Fetz TH, Dienemann H, Hoffmann H, Herth FJF, Meister M, Ebert W.: Tumor Volume and Tumor Marker Index Based on CYFRA 21-1 and CEA are Strong Prognostic Factors in Operated Early Stage NSCLC. **Lung Cancer** 2008, 60, 408-415

